icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
GefuSHhN6PQdw0KN
Listen
